Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

HH-3806

Alternative Names: HH-3806, HH 3806, HH3806
Clinical Status: Active
Latest Update: 2024-02-20
Latest Update Note: Clinical Trial Update

Product Description

Haihe Biopharma is developing a BET-BD2 Inhibitor, HH3806 where the first patient has been dosed in Australia. (Sourced from: https://www.haihepharma.com/en/news/details/363)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Tigermed Australia Pty Ltd
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HH-3806

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
ACTRN12622001339741

P1

Recruiting

Lymphoma, Non-Hodgkin

2025-02-28

2024-11-19

Treatments

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions